AURA Stock — Aura Biosciences Inc.: Cash, EV, Pipeline

Share price

$6.44

Market cap

$667.9M

Cash

$323.8M

Enterprise value

$344.1M

Balance sheet

Cash	$323.8M
Debt	$0.0M
Net cash	$323.8M
Enterprise value	$344.1M
Basic shares	103.5M shares
Fully diluted shares	133.7M shares
Fully diluted market cap	$861.2M
Cash per share	$3.13

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AURA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 11 - Feb 22	AU-011	Phase 2	Eye Cancer; Primary Cancer	—
Apr 12 - May 24	AU-011	Phase 1	Non-muscle-invasive Bladder Cancer; NMIBC; Non-Muscle Invasive Bladder Carcinoma	—
Dec 27, 2027 - Feb 7, 2028	Bel-sar	Phase 3	Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Belzupacap sarotalocan

Phase 3 · Active Modality: virus-like drug conjugate (VDC)

Aliases bel-sar

Target Modified tumor-associated glycosaminoglycans / heparan sulfate proteoglycans (HSPGs)

Indications

Early choroidal melanoma (small choroidal melanoma and/or indeterminate lesions) (Phase 3)
Metastases to the choroid (Phase 2)
Cancers of the ocular surface (Phase 1)
Non-muscle invasive bladder cancer (NMIBC) (Phase 1)

Catalysts

— second half of 2027

Status note Only product candidate; company heavily dependent on its success. Global Phase 3 CoMpass trial under Special Protocol Assessment with FDA; enrollment completed. NMIBC Phase 1b/2 interim data announced August 2026. No revenue to date.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Bel-sar
Lead indication	Choroidal Melanoma
Lead phase	Phase 3
Active trials	6

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06007690	Phase 3	Active, not recruiting	Sponsor	Aura Biosciences	—	Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma	—
NCT06643884	Phase 2	Recruiting	Sponsor	Aura Biosciences	—	Eye Cancer; Primary Cancer	—
NCT05483868	Phase 1	Active, not recruiting	Sponsor	Aura Biosciences	—	Non-muscle-invasive Bladder Cancer; NMIBC; Non-Muscle Invasive Bladder Carcinoma	—
NCT07421739	Not disclosed	Recruiting	Sponsor	Aura Biosciences	—	Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma	—
NCT03941379	Not disclosed	Active, not recruiting	Sponsor	Aura Biosciences	—	Choroidal Melanoma; Indeterminate Lesions of Eye	—
NCT07338968	Not disclosed	Enrolling by invitation	Sponsor	Aura Biosciences	—	Choroidal Melanoma; Indeterminate Lesions	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Aura Biosciences on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	7,100,000	+2,000,000	1.10%	2026-08-14
OrbiMed Advisors	3,333,333	+3,333,333	0.45%	2026-08-14
ADAR1 Capital Management	130,152	+130,152	0.04%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

AURA — Aura Biosciences Inc.